UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 82

Sortiert nach

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

The New England journal of medicine, 2020-09, Vol.383 (10), p.931-943

2020

Link zum Volltext

Verfügbarkeit prüfen

The Presence of EGFR T790M in TKI-Naïve Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare

Cancers, 2022-07, Vol.14 (14), p.3511

2022

Link zum Volltext

Verfügbarkeit prüfen

A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses

Cancers, 2021-07, Vol.13 (14), p.3641

2021

Link zum Volltext

Verfügbarkeit prüfen

CX Chemokine Receptor 7 Contributes to Survival of KRAS -Mutant Non-Small Cell Lung Cancer upon Loss of Epidermal Growth Factor Receptor

Cancers, 2019-03, Vol.11 (4), p.455

2019

Link zum Volltext

Verfügbarkeit prüfen

An All-In-One Transcriptome-Based Assay to Identify Therapy-Guiding Genomic Aberrations in Nonsmall Cell Lung Cancer Patients

Cancers, 2020-10, Vol.12 (10), p.2843

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion–positive non–small cell lung cancer

Cancer, 2024-03, Vol.130 (5), p.683-691

2024

Link zum Volltext

Verfügbarkeit prüfen

Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy

Cancer and metastasis reviews, 2020-09, Vol.39 (3), p.999-1013

2020

Link zum Volltext

Verfügbarkeit prüfen

Molecular imaging biomarkers for immune checkpoint inhibitor therapy

Theranostics, 2020, Vol.10 (4), p.1708-1718

2020

Link zum Volltext

Verfügbarkeit prüfen

CT‐guided percutaneous hookwire localization increases the efficacy and safety of VATS for pulmonary nodules

Journal of surgical oncology, 2017-06, Vol.115 (7), p.898-904

2017

Link zum Volltext

Verfügbarkeit prüfen

Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers

Cancers, 2018-01, Vol.10 (1), p.10

2018

Link zum Volltext

Verfügbarkeit prüfen

Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study

The Lancet regional health. Europe, 2023-04, Vol.27, p.100592-100592, Article 100592

2023

Link zum Volltext

Verfügbarkeit prüfen

Molecular imaging to support cancer immunotherapy

Journal for immunotherapy of cancer, 2022-08, Vol.10 (8), p.e004949

2022

Link zum Volltext

Verfügbarkeit prüfen

Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib

Translational lung cancer research, 2021-03, Vol.10 (3), p.1525-1535

2021

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

NPJ precision oncology, 2024-05, Vol.8 (1), p.113-113

2024

Link zum Volltext

Verfügbarkeit prüfen

Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing

PloS one, 2016-04, Vol.11 (4), p.e0153065-e0153065

2016

Link zum Volltext

Verfügbarkeit prüfen

Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort

Translational lung cancer research, 2022-12, Vol.11 (12), p.2495-2506

2022

Link zum Volltext

Verfügbarkeit prüfen

Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC

Targeted oncology, 2021-03, Vol.16 (2), p.215-226

2021

Link zum Volltext

Verfügbarkeit prüfen

Chronic Obstructive Pulmonary Disease Is Not Associated with KRAS Mutations in Non-Small Cell Lung Cancer

PloS one, 2016-03, Vol.11 (3), p.e0152317-e0152317

2016

Link zum Volltext

Verfügbarkeit prüfen

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification

Frontiers in oncology, 2018-05, Vol.8, p.176

2018

Link zum Volltext

Verfügbarkeit prüfen

A Novel EGFR Mutation in Exon 19 Showed Stable Disease After TKI Treatment

Journal of thoracic oncology, 2012-08, Vol.7 (8), p.e8-e8

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 82

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(74)
Mit Volltextzugriff
(76)

Publikationsform

Artikel
(80)
Berichte
(2)

Sprache

Englisch
(82)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(52)
Life Sciences & Biomedicine
(50)
Oncology
(37)
Humans
(27)
Lung Cancer
(21)
Mutation
(21)
Non-Small Cell Lung Cancer
(19)
Non-Small Cell Lung Carcinoma
(16)
Lung Neoplasms - Drug Therapy
(15)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(13)
Patients
(13)
Respiratory System
(13)
Lung Neoplasms - Genetics
(12)
Carcinoma, Non-Small-Cell Lung - Genetics
(11)
Small Cell Lung Carcinoma
(11)
Female
(10)
Male
(10)
Middle Aged
(10)
Tumors
(10)
Metastasis
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

The Presence of EGFR T790M in TKI-Naïve Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare

Amivantamab Compared with Real-World Physician’s Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations

A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses

CX Chemokine Receptor 7 Contributes to Survival of KRAS -Mutant Non-Small Cell Lung Cancer upon Loss of Epidermal Growth Factor Receptor

An All-In-One Transcriptome-Based Assay to Identify Therapy-Guiding Genomic Aberrations in Nonsmall Cell Lung Cancer Patients

A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion–positive non–small cell lung cancer

Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy

Molecular imaging biomarkers for immune checkpoint inhibitor therapy

CT‐guided percutaneous hookwire localization increases the efficacy and safety of VATS for pulmonary nodules

NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations

Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers

Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study

Molecular imaging to support cancer immunotherapy

Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)

Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort

Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC

Chronic Obstructive Pulmonary Disease Is Not Associated with KRAS Mutations in Non-Small Cell Lung Cancer

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR -mutated nonsmall cell lung cancer

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification

A Novel EGFR Mutation in Exon 19 Showed Stable Disease After TKI Treatment

Suchergebnisse filtern